That is nearly a year of continuous treatment, and the results paint a clear picture of what happens when people stay on this compound without interruption
Noguchi R, Nakayama K, Itoh M, Kamohara K, Furukawa K, Oyama JI, Node K, Morita S (2016) Development of a three-dimensional pre-vascularized scaffold-free contractile cardiac patch for treating heart disease
This allows your provider to identify contributing factors and determine whether GLP-1 therapy may be appropriate based on your goals and medical profile
Here is one example research week for the 10 mg vial at 150 mcg (45 units), dosed in the morning
Prozorovski, T., Schneider, R., Berndt, C., Hartung, H.-P
(4) Vergleichende Struktur-Aktivitaets-Beziehungsstudien (SAR) mit anderen GLP-1-Analoga